4.7 Review

The P2X7 receptor as a new pharmacological target for retinal diseases

Journal

BIOCHEMICAL PHARMACOLOGY
Volume 198, Issue -, Pages -

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2022.114942

Keywords

Diabetic retinopathy; Age-related macular degeneration; Glaucoma; Inflammation

Funding

  1. University of Catania
  2. MUR grant PRIN [2020FR7TCL]
  3. [2020/2022]

Ask authors/readers for more resources

The activation of P2X7 receptor is implicated in the pathophysiology of various retinal age-related diseases, making it a potential pharmacological target for preventing these devastating conditions.
Purinergic ionotropic receptors, such as the P2X7 receptor, are activated by extracellular adenosine triphosphate (ATP). The P2X7 receptor is a trimeric ATP-gated cation channel and its activation results in several downstream events, including the release of proinflammatory mediators and cell damage. The P2X7 receptor has been studied as a pharmacological target for inflammatory and neuroinflammatory diseases, and preclinical studies have recently provided evidence that P2X7 receptor activation is implicated in pathophysiology of several retinal agerelated diseases. These diseases are devastating conditions that have an deep impact on the quality of life of patients and on the health systems of all countries. In this review, we discuss the role of the P2X7 receptor in retinal age-related conditions such as glaucoma, age-related macular degeneration, and diabetic retinopathy. Furthermore, we focus on the pharmacological modulation of the P2X7 receptor that could have a relevant clinical impact to prevent retinal diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available